VA DoD

Echosens™ is proud to partner with the Veterans Administration and Department of Defense.

The Veterans Association (VA) is the largest single hepatitis C care provider in the United States

In 2015, the VA set out to eradicate HCV in their patient population. Today, the VA has accomplished their goal of healing 100,000 veterans of HCV and have relied on FibroScan to be a crucial tool in this endeavor.

But curing HCV doesn’t cure underlying liver health related complications. The worldwide epidemic of liver disease is still rapidly growing, and the VA is no exception, even with proven treatments for HCV.

In addition to the 300 million people worldwide who are unaware that they are living with viral hepatitis, potentially 1 billion are living with another affliction of the liver known as non-alcoholic fatty liver disease, or NAFLD. NAFLD is the result of too much fat in the liver and is directly correlated to the growing twin epidemics of obesity and type 2 diabetes mellitus.

Nearly 1.5 million veterans are being treated by the VA for type 2 diabetes, and these veterans are highly susceptible of developing NAFLD and potentially progressing to a more nefarious development of NAFLD called non-alcoholic steatohepatitis (NASH). Additionally, 3.22 million VA patients do not have access to a VA Medical Center and receive routine care through CBOCs and Veterans Choice.

Dr. Edward Mena, Pasadena Liver Center

Pasadena Liver Center

"As expected, NAFLD identified in patients prior to treatment persisted after curing their HCV infection. Particularly concerning was that among those with NAFLD before treatment, 6.25% still had significant liver scarring after their HCV infection was cured, while those without liver fat before being treated did not have the level of scarring. While more research is needed, this new study reinforces the need to continue to monitor liver health in those patients who are cured of HCV infection.”

Dr. Edward Mena
Pasadena Liver Center
Pasadena CA
Read Full Paper Here

Too much fat in liver cells

NAFLD is associated with obesity, insulin resistance, diabetes and other metabolic risk factors, and is directly related to too much fat in the liver cells.

If left untreated, NAFLD can progress to NASH which may lead to cirrhosis of the liver with complications of hepatocellular carcinoma (HCC), liver failure and liver related death or the requirement of liver transplantation. In addition to liver-related morbidity and mortality, subjects with NASH are at an increased risk of cardiac morbidity and mortality.

The American Diabetes Association (ADA) has released new guidelines recommending all patients with Type 2 diabetes be screened for NAFLD.

Dustin Lee, Owner & President Fidelis Sustainability Distribution, LLC

Fidelis Sustainability Distribution, LLC

“The great advantage of FibroScan is that they allow veterans to avoid the invasive and sometimes painful biopsies often used to detect liver disease. The FibroScan technology has been a valuable tool in this fight, and has truly helped many of my veteran brothers and sisters at the VA.”

Dustin Lee, Owner & President
Fidelis Sustainability Distribution, LLC
USMC scout sniper veteran and principal

View Guidelines

FibroScan® is a non-invasive, painless and quick procedure, designed to provide consistent measurements of both VCTE and CAP and has allowed the VA to efficiently and cost effectively identify patients with HCV. FibroScan will be monumental in helping the department identify veterans at risk for NAFLD.

View Guidelines Here

Fidelis Sustainability Distribution (FSD)

FSD is a Service Disabled Veteran Owned Small Business (SDVOSB) whose team comprises a vast array of work experience in the med-tech industry. Bringing together their collective expertise, they are able to comprehensively identify, vet out, and support only the best technologies. Their goal is to leverage their unique experience and bring these technologies to US government locations worldwide.

FibroScan is a non-invasive, painless and quick procedure, designed to provide consistent measurements of both VCTE and CAP and has allowed the VA to efficiently and cost effectively identify patients with HCV. FibroScan will be monumental in helping the department identify veterans at risk for NAFLD.

Fibroscan is Available for immediate requisition under the terms of IDIQ Contract VA119-17- D-0033

Find A VA Near You

No categories found

No results found in this location. Please try again.

Find out how FibroScan Gateway can help the VA & CBOCs with managing their liver patient population

Visit FibroScan Gateway

Contact A Representative

In North America there are over 1200+ FibroScan systems in operation & we’re growing!

Speak to a Representative